Yutrepia Gets Tentative Approval for Pulmonary Arterial Hypertension
Yutrepia is an inhaled dry powder formulation of tresprostinil delivered through a palm-sized device.
Pulmonary Hypertension
Tyvaso DPI Approval Decision Delayed Over Inspection Issue
Tyvaso DPI is an investigational drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Inhaled Treprostinil and Lung Function in Patients With PH-ILD and PAH
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
Inhaled Imatinib Designated Orphan Drug for Pulmonary Arterial Hypertension
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
Midodrine Cuts Recurrent Syncope in Young, Healthy Patients
Absolute risk reduced by 19 percentage points, with number needed to treat to prevent syncope of 5.3
FDA Approves IV Formulation of Uptravi for Pulmonary Arterial Hypertension
The approval was based on data from a single sequence cross-over phase 3 study that evaluated the safety, tolerability and pharmacokinetics of temporarily switching between the tablet and IV formulation.
FDA to Review Dry Powder Inhalation Formulation of Tyvaso
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil.
Case Report: Vitamin C Rapidly Reverses Pulmonary HTN Secondary to Scurvy
Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).
Sotatercept Reduces Pulmonary Vascular Resistance in PAH
Decrease in pulmonary vascular resistance at 24 weeks greater with sotatercept versus placebo for pulmonary arterial hypertension
Tyvaso Approved for Pulmonary Hypertension With Interstitial Lung Disease
The sNDA approval is supported by data from the phase 3 INCREASE study that evaluated Tyvaso inhalation solution in 326 adults with PH-ILD.
